All In Biotech

Drug Trial Radar · NCT06777316

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Jan 22, 2025

Primary completion

Mar 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Cogent Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jan 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.

Conditions

  • Intrahepatic Cholangiocarcinoma (Icc)
  • Cholangiocarcinoma
  • Other Solid Tumors, Adult
  • FGFR2 Gene Fusion/Rearrangement
  • FGFR2 Gene Amplification
  • FGFR2 Gene Short Variants
  • FGFR3 Gene Fusion/Rearrangement
  • FGFR3 Gene Amplification
  • FGFR3 Gene Short Variants
  • FGFR2 Genetic Alterations
  • FGFR3 Genetic Alterations
  • Advanced Solid Tumors

Interventions

  • CGT4859Drug

    CGT4859 is a selective FGFR2/3 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - AEsTime frame: Approximately 12 months
  2. Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - Laboratory resultsTime frame: Approximately 12 months
  3. Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - ECG resultsTime frame: Approximately 12 months
  4. Phase 2: Evaluate antitumor activity of CGT4859 - Objective Response Rate (ORR)Time frame: Approximately 8 months

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Institute

    Palo Alto, California

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Chicago Medicine Comprehensive Cancer Center

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • The Christ Hospital

    Cincinnati, Ohio

  • Taussig Cancer Center - Cleveland Clinic

    Cleveland, Ohio

  • Fox Chase cancer Center

    Philadelphia, Pennsylvania

  • Tennessee Oncology

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute - University of Utah

    Salt Lake City, Utah

  • Princess Margaret Cancer Centre - UHN

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.